FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Taub Rebecca (Last) (First) (Middle) C/O MADRIGAL PHARMACEUTICALS 200 BARR HARBOR DRIVE, SUITE 200 (Street) WEST	, INC.	Issuer Name and Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS, INC. [MDGL] Date of Earliest Transaction (Month/Day/Year) 01/16/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)									is. Relationship of Reporting Person(s) to Check all applicable) X Director 10% X Officer (give title below) below Pres., R&D, and CMO is. Individual or Joint/Group Filing (Checkine)					wner specify pplicable
CONSHOHOCKEN PA 19428 (City) (State) (Zip)											X		filed by Mo		oorting Pers an One Rep	- 1
Table I - No			_			uired,	Dis	posed of,	or B	enefic	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			Execution Da			3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Secur Benet		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code					v	Amount	(A) o (D)	Pric	e:e		ction(s)			,
Common Stock	01/16/2	2023				A ⁽¹⁾		20,001	A	\$0	0.00	20,001(1)			D	
Common Stock												43	434,758		D	
Common Stock												655,540			I	By SQN, LLC ⁽²⁾
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
Security or Exercise (Month/Day/Year) if any	emed ion Date, /Day/Year)	4. Transa Code (I 8)		ion of		6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Der Sed (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
Explanation of Pospensor		Code	v	(A)	(D)	Date Exercis	able	Expiration Date		Amount or Number of Shares						

- 1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
- 2. The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

**As attorney-in-fact for Reporting Person

/s/ Brian J. Lynch**

01/18/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.